January 25, 2024 Lab Top-10 Liq. Handling & Robotics M&A, Partnerships

Bruker Announces Agreement to Acquire Chemspeed

Chemspeed Accelerates Bruker’s Laboratory Automation and Digitalization Drive BASEL, Switzerland–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, aSwiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research... Read more

December 29, 2023 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas LumiraDx’s technology integrates multiple Point of Care tests on a simple to use single instrument and brings more affordable and accessible testing to patients worldwide Under the terms of the agreement,... Read more

December 6, 2023 Environ, Ag./Food & Bev Lab Top-10 M&A, Partnerships Product Launch

Thermo Fisher Scientific Establishes 2030 Renewable Electricity Goal and Solar Power Purchase Agreement with ib vogt

Thermo Fisher Scientific Establishes 2030 Renewable Electricity Goal and Solar Power Purchase Agreement with ib vogt Share of 127-megawatt aggregated deal in collaboration with Eurofins Scientific will power over half of Thermo Fisher’s addressable European footprint with 100% renewable electricity by 2025 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in... Read more

December 4, 2023 Clinical Research/Diagn. M&A, Partnerships

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes

Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche’s in-house assets Lead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbidities Under the terms of... Read more

November 28, 2023 Environ, Ag./Food & Bev Lab Top-10 Licensing, IP, and Legal M&A, Partnerships PAI Top-10 Product Launch

Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences

Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences WALTHAM, Mass. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, today announced the formation of a strategic... Read more